SCHAUMBURG, Ill., May 18, 2012 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Atracurium Besylate Injection, USP, the generic form of the neuromuscular blocker Tracrium®, in 50 mg per 5 mL latex-free vials. According to IMS data for the twelve-months ended March 2012, the U.S. market for Atracurium approximated $2.4 million. As with all products in Sagent's portfolio, Atracurium features the company's PreventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors.
"Atracurium is currently on the FDA and ASHP shortage lists with very limited availability," said Jeffrey M. Yordon, President, Chief Executive Officer and Chairman of the Board of Sagent. "We are pleased to offer customers a source of this important anesthetic product and help to alleviate another product shortage."
About Atracurium Besylate Injection, USP
Atracurium Besylate Injection is a nondepolarizing skeletal muscle relaxant. It is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
The package insert, which is available at www.sagentpharma.com, contains detailed information about the indications, complete side effect profile, and prescribing information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive pharmaceutical product portfolio that fulfills the evolving needs of patients.